NeuMoDx now a QIAGEN Company
We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible. This includes the QIAstat-Dx Analyzer and Assay Panels – QIAGEN’s syndromic testing solution – and the QIAsymphony-RGQ System – QIAGEN’s premier Sample to Insight workflow solution.
The acquisition is driven by our ambition to address laboratory needs in almost any setting for molecular diagnostics. By integrating the NeuMoDx molecular systems into our portfolio, we add unique compact systems that offer true random access, fast turnaround time, full automation and a comprehensive menu of 13 CE-IVD-marked assays for different infectious diseases in Europe, with plans to accelerate and broaden the U.S menu as well. A new multiplex test for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2 is scheduled to launch in the fourth quarter of this year.
What does this mean for you? Logistically, the way in which you order NeuMoDx products will remain the same. Moving forward, you can expect increased dedication to customer needs, with plans in the works for significant manufacturing ramp up, assay menu expansion, and global distribution.
We thank you for your continued support during this time and we will keep you updated regularly during the integration process. If you have any questions, please feel free to contact us.